| Bernstein: Teva has upside potential |
Middle East North Africa Financial NetworkThe fourth catalyst is a Cephalon drug, TR-Hydrocodone, a tamper-resitant oral opioid alternative to Oxycodone pain reliever, which is in the final stages of a Phase III clinical trial, after which Teva will file with the FDA.
|
| Teva: Drug pipeline fuels rock-solid growth |
MSN MoneyTeva's latest proposed purchase of Cephalon will add more than 10% to sales in 2012 and offers rapid growth opportunities. And its joint venture with Procter & Gamble in Europe, whereby P&G supplies the marketing and TEVA makes the drug and health ...
|
| Case study—Nuvigil: Pay for Play |
Medical Marketing and MediaShawn Ferry, senior group director, Wake (CNS) franchise, at Teva's Cephalon unit, used pay-for-performance (P4P) marketing to help raise awareness of excessive sleepiness, a condition which Cephalon's flagship brand, Nuvigil, is approved to treat.
|
| Sokolove Law, LLC | Treanda has been Issued a Recalled For Possible Glass ... |
Linex Legal (press release) (registration)by Sokolove Law Staff on Feb 06 2012 Cephalon Inc. has issued a recall of Treanda, an injection used to treat leukemia, after glass fragments were found by the US Food and Drug Administration in one vial of the medication. According to the FDA, ...
|
| Treanda (bendamustine HCL): Recall |
Healthcare PackagingISSUE: Cephalon, Inc. notified healthcare professionals of a recall of Treanda (bendamustine HCL) for Injection 25mg/8mL, lot TB30111, expiration date 12/2012. This product lot is being recalled due to the presence of particulate matter found in a ...
|
| Valeant Withdraws ISTA Offer |
NASDAQLast year, Valeant Pharma had proposed to acquire Cephalon Inc. for $73 per share. Cephalon's Board of Directors rejected Valeant Pharma's take-out bid as they found the offer too low and not in the best interest of its shareholders.
|
| Valeant Withdraws ISTA Offer |
Daily Markets (blog)Last year, Valeant Pharma had proposed to acquire Cephalon Inc. for $73 per share. Cephalon's Board of Directors rejected Valeant Pharma's take-out bid as they found the offer too low and not in the best interest of its shareholders.
|
